12 August 2023 : Clinical Research
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment
Yusuke Nomoto1ABCDEF*, Makoto Furihata1ABCDEF, Haruka Hagiwara1F, Hirotaka Ishino1B, Shintaro Yano1D, Hiroki Okawa1B, Yoichi Nakatsu1B, Kumiko Noda1B, Shinjiro Nishi1F, Shingo Ogiwara1AB, Tsuneo Kitamura1D, Taro Osada1AGDOI: 10.12659/MSM.941285
Med Sci Monit 2023; 29:e941285
Table 1 Patient background and demographic data.
| Number | ||
|---|---|---|
| Sex | Male | 21 (48.8%) |
| Female | 22 (51.2%) | |
| Age | 68.1±8.0 years old (range: 46–79) | |
| Comorbidities | 1) Psychiatric | 4 (9.3%) |
| 2) Collagen disease | 3 (7.0%) | |
| 3) Metabolic disease | 9 (20.9%) | |
| 4) Malignancy | 4 (9.3%) | |
| 5) Respiratory | 2 (4.7%) | |
| 6) Cardiovascular | 8 (18.6%) | |
| 7) Post-abdominal surgery | 7 (16.3%) | |
| 8) Orthopedic | 2 (4.7%) | |
| Total | 39 (90.7%) | |
| Body mass index | 20.5±3.3kg/m (range: 14.4–27.3) | |
| Duration of PD | 11.0±6.0 years (range: 2–27) | |
| MDS-UPDRS motor score | 26.4±13.3 (range: 4–59) | |
| Prior treatment | Levodopa | 43 (100.0%) |
| Dopamine agonists | 40 (93.0%) | |
| Norepinephrine replacers | 1 (2.5%) | |
| COMT inhibitors | 12 (27.9%) | |
| MAO inhibitors | 15 (34.9%) | |
| Adenosine A2A receptor antagonist | 14 (32.6%) | |
| Anticholinergic agents | 4 (9.3%) | |
| Amantadine hydrochloride | 6 (14.0%) | |
| Botulinum toxin type A | 1 (2.5%) | |
| Antiepileptic agent (Zonisamide) | 6 (14.0%) | |
| PD – Parkinson’s disease; MDS-UPDRS – Movement Disorder Society Unified Parkinson’s Disease Rating Scale; COMT – catechol-O-methyltransferase; MAO – monoamine oxydase. | ||